Transduced deoxyribonucleoside kinases (dNK) can be used to kill recipient cells in combination with nucleoside prodrugs. The Drosophila melanogaster multisubstrate dNK (Dm-dNK) displays a superior turnover rate and has a great plasticity regarding its substrates. We used directed evolution to create Dm-dNK mutants with increased specificity for several nucleoside analogs (NAs) used as anticancer or antiviral drugs. Four mutants were characterized for the ability to sensitize Escherichia coli toward analogs and for their substrate specificity and kinetic parameters. The mutants had a reduced ability to phosphorylate pyrimidines, while the ability to phosphorylate purine analogs was relatively similar to the wild-type enzyme. We selected two mutants, for expression in the osteosarcoma 143B, the glioblastoma U-87M-G and the breast cancer MCF7 cell lines. The sensitivities of the transduced cell lines in the presence of the NAs fludarabine (F-AraA), cladribine (CdA), vidarabine and cytarabine were compared to the parental cell lines. The sensitivity of 143B cells was increased by 470-fold in the presence of CdA and of U-87M-G cells by 435-fold in the presence of F-AraA. We also show that a choice of the selection and screening system plays a crucial role when optimizing suicide genes by directed evolution.
Introduction
Deoxyribonucleoside kinases (dNKs) catalyze the phosphorylation of deoxyribonucleosides (dN) to deoxyribonucleoside monophosphates and contribute thereby to the supply of DNA precursors, deoxyribonucleoside triphosphates. Humans have four dNKs with overlapping specificities. 1 Thymidine kinase 1 (TK1, EC 2.7.1.21) is strictly specific for thymidine (Thd) and deoxyuridine (dUrd). Thymidine kinase 2 (TK2, EC 2.7.1.21) phosphorylates not only Thd and dUrd, but also deoxycytidine (dCyd). The deoxyguanosine kinase (EC 2.7.1.113) phosphorylates deoxyadenosine (dAdo) and deoxyguanosine (dGuo), while the deoxycytidine kinase (dCK, EC 2.7.1.74) phosphorylates dAdo, dGuo and dCyd. In general, dNKs can be divided into two superfamilies, the TK1-like family and the non-TK1-like family. 2 Recently, these two families have been shown to have a completely different structural scaffold indicating a different evolutionary origin. The TK1-like family contains a structural zinc and has a very rigid substrate selectivity, 3 while the non-TK1-like family has a great plasticity with respect to the substrates they accept and their substrate specificities can be changed by an exchange of only a single amino acid. [4] [5] [6] A large variability in the potential to activate various analogs has a clear biomedical relevance.
dNKs play a key role in the chemotherapeutic treatment of cancer and viral diseases as they catalyze the first, and often the rate-limiting step of nucleoside analog (NA) activation. 1 These enzymes have therefore been the prime candidates to be used as suicide genes in gene therapy of cancer. The basic principle is to transduce a cancer cell with a gene coding for a foreign kinase, for example the thymidine kinase of herpes simplex virus 1 (HSV1-TK), and subsequently expose the cell to an NA. The activation of the NA to a cytotoxic compound is then increased by the transduced kinase. [7] [8] [9] An ideal suicide candidate would exhibit a highly different and increased selectivity and preferably also a higher catalytic turnover for the NA than the human enzymes.
An attractive approach is to engineer or in vitro breed a kinase for improved performance in selected suicide gene prodrug combinations as exemplified by HSV1-TK and the nucleoside analogs azidothymidine (AZT), ganciclovir and acyclovir. [10] [11] [12] We have extensively studied multisubstrate dNKs (EC 2.7.1.145) from insects during the last years, such as Drosophila melanogaster, Bombyx mori and Anopheles gambiae that are capable of efficiently phosphorylating all four natural dNKs. [13] [14] [15] [16] The multisubstrate dNK from D. melanogaster (Dm-dNK) combines this property with exceptional high turnover rates and the first attempts of random and directed mutagenesis have shown that its substrate specificity can be easily manipulated. 5, 6, 17 Furthermore, it has been shown that Dm-dNK and mutants made by directed mutagenesis, when transduced into the osteosarcoma cell line 143B, can increase its sensitivity toward several NAs. 18, 19 However, so far there have only been a limited number of attempts 6, 12 to determine the qualitative and quantitative relationships between the biochemical parameters of the suicide enzymes and how they subsequently govern the sensitivity of the target cells toward NAs.
In this study, we used previously described mutants of Dm-dNK generated by directed evolution 6 to further improve their performance by random combination in selected suicide gene prodrug combinations. Special emphasis was put on how and if the chosen selection system and in vitro kinetic characterization can predict the performance of the mutants chosen. We found two new Dm-dNK mutant-purine NA combinations with the well-known anticancer drugs, cladribine (CdA) and fludarabine (F-AraA), the active metabolite of fludara phosphate, that increased the sensitivity of the tested cancer cell lines.
Results

Development and screening for Dm-dNK mutants
Sixteen mutant Dm-dNK genes, which had previously been generated by mutagenic PCR, 6 were cut into two pieces by PstI and shuffled together to form a random library. After transformation into the TK-deficient Escherichia coli strain KY895, 192 ampicillin-resistant colonies were taken and tested on the selective plates containing the NAs AraC, AZT, ddA, ddC, CdA and AraA. Note that the expression from the plasmids was driven by the basal level promoter expression and no inducer was employed. The concentration of analogs was chosen to be lower than the lethal dose (LD 100 ) values of AraC, AZT, ddA and ddC determined for the Dm-dNK mutants MuA-MuH. 6 Therefore, only mutants which sensitized the E. coli tester strain stronger than the mutants MuA-MuH, were collected. In addition to the four previously tested analogs, the transformants were tested also on CdA and AraA. Four colonies were found by this screening and then confirmed by a second round of testing. The inserts in the respective plasmids were sequenced to determine the mutations' position ( Table 1) . As expected, all mutants had two parts, derived from two different precursors. B2 originates from MuC and MuA (the N-and the C-terminal parts, respectively), B5, B10 and B15 have their C-terminal part from MuB. The N termini from B5, B10 and B15 are from MuC, MuD and MuH, respectively.
Subsequently, the LD 100 values for all six NAs used in screening and F-AraA with all four mutants were determined ( Table 1 ). The maximum decrease of LD 100 when compared to the lowest LD 100 reported for the best parental clones in the library 6 was 31.6-fold for AraC, ddA and ddC. The improvements on CdA, AraA and F-AraA were in the range of 3-10 times. However, no further improvements were found for AZT. Except for B10, the other three B mutants displayed decreased LD 100 values for at least two of the other tested NAs, CdA, AraA or F-AraA when compared to wild-type Dm-dNK. Two mutants, B5 and B15, showed decreased LD 100 for all seven tested NAs, when compared to wild-type Dm-dNK. In the following we have compared these data with the kinetic parameters for purified recombinant mutant enzymes.
Purification and in vitro characterization
The four Dm-dNK mutants B2, B5, B10 and B15 were overexpressed in E. coli as fusion proteins with an N-terminal glutathione S-transferase (GST) fusion tag and purified by gluthatione-Sepharose affinity chromatography followed by thrombin cleavage. Calculated on Abbreviations: AraA, vidarabine; AraC, cytarabine; AZT, azidothymidine; CdA, cladribine; ddA, dideoxyadenosine; ddC, zalcitabine; Dm-dNK, Drosophila melanogaster multisubstrate deoxyribonucleoside kinase; F-AraA, fludarabine. The concentrations are shown which cause 100% lethality of KY895 transformed with the plasmid vector (pGEX-2T), wild-type Dm-dNK and each mutant. The values are the average from 2 to 4 independent experiments. The lowest LD 100 value for each nucleoside analog is shaded in gray. The position of amino-acid exchanges is shown, silent mutations are not shown. The arrow marks the two parts of the mutants that were generated by PstI digest. a Data from Knecht et al. Purine-specific Dm-dNK mutants W Knecht et al the basis of a 1l culture, we could isolate 0.6, 0.7, 1 and 1.1 mg of nearly homogenous rB2, rB5, rB10 and rB15, respectively, as judged by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) ( Figure 1 ). Note that rB2 migrates slightly faster on the SDS-PAGE than the other mutants, probably caused by an altered SDS binding due to the mutations.
The relation between the reaction velocity and substrate concentration was determined for the four natural dNs and several NAs ( Table 2 ). In general, all mutants showed a more prominent decrease in the efficiency of Thd phosphorylation than in the efficiency of the other tested substrates. The kinetic pattern for some of the mutants deviated from the wild type as they gained cooperativity. rB2 and rB5 showed extreme positive cooperativity with Thd as the substrate, with Hill coefficients (h) of 7.5 and 8.6, respectively ( Figure 2 ). In addition, rB5 and rB15 showed positive cooperativity with dCyd, and rB10 showed negative cooperativity with dCyd (Table 2 ). rB15 also displayed positive cooperativity with CdA and rB2, rB5, and rB15 with AraA as well.
For Thd, all B mutants showed increased K m values and decreased V max values, giving k cat /K m values, which were 5000-to 20 000-fold lower than the wild-type enzyme values. A similar trend, increased K m and lowered V max , was observed for dCyd, and k cat /K m values were in general 100-to 1000-fold lower. Thd is the best substrate for rDm-dNK, whereas dCyd became the most preferred substrate for rB2, rB5 and rB15. In conclusion, the B mutants had a significantly decreased ability to phosphorylate pyrimidine-native substrates. For the native purines, K m values were almost unchanged but V max values were lower. This resulted in k cat /K m values that were only 10-to 100-fold lower than for the wild type. As a consequence, the B mutants exhibited similar specificities for pyrimidines and purines. In the case of analogs there was a general tendency that the K m values remained similar to the wild-type ones, while V max values were lower and therefore the k cat /K m values were in general 1-to -10-fold lower compared to the wild-type enzyme. For example, for F-AraA the values were within the same range, while for CdA they were approximately 10 times lower. Apparently, in B mutants the decrease of k cat /K m for the native substrates was much more profound than for analogs. rB10 catalyzed the phosphorylation of CdA more efficiently than the natural substrates. Three of the mutants even showed an increased ability to phosphorylate the NA AraA. Could these parameters predict the behavior of mutants in the bacterial or mammalian cell?
The specificity of each enzyme for a single NA has been described previously using the equation
. 6, 12 The equation assumes that the concentrations of the native nucleosides are similar in the systems compared. The increase in specificity (-fold) of the Dm-dNK mutants when compared to wild-type Dm-dNK in phosphorylating the different NAs in Table 2 was calculated (Table 3) . It can be seen that the specificity of each mutant for each NA increased compared to wild-type Dm-dNK and the mutant rB10 showed the most improved properties in vitro. However, the results from the kinetic studies of the recombinant enzymes could not predict or explain the quantitative aspect of the LD 100 determination results. In other words, from the kinetic studies of the conversion of substrates and NAs in vitro, we could not explain why B5 and B15 mutants were so successful in sensitizing E. coli against CdA and why B10 sensitized E. coli so efficiently with AZT, compared to the other mutants.
Sensitivity of transduced human cancer cell lines
Based on the above experiments, we decided to test two mutants, B5 and B10, for their ability to increase the sensitivity of human cancer cells toward NAs and then compare the results to the E. coli and kinetic parameters. B5 and B10 mutants were either characterized by dramatically decreased LD 100 values in the E. coli growth tests (Table 1) or showed the most improved specificities in the kinetic experiments (Table 3 ). The cell lines used were the osteosarcoma cell line 143B, the glioblastoma cell line U-87-MG and the breast cancer cell line MCF7. All three lines were tested with F-AraA. 143B and U-87-MG were also tested with CdA. AraC was tested with 143B and AraA with MCF7. The results are summarized in Table 4 . B5 increased the sensitivity of 143B toward CdA by 470-fold while B10 increased the sensitivity 435-fold with F-Ara A in the U-87-MG cell line. However, none of the mutants tested increased the sensitivity of MCF7 toward F-AraA or AraA by more than sevenfold.
In general, a significant increase in the sensitivity to F-Ara of both 143B and U-87-MG cell lineages was found when transduced with the mutants B5 and B10 in comparison to the untransduced or wild-type Dm-dNK-transduced cells. However, these values are below the increase in specificity predicted by the determined kinetic parameters for the substrates, which suggest a 140-or 480-fold increase, respectively (Table 3) . These changes were not at all predictable from the E. coli data (Table 1) since the LD 100 value for F-AraA could not be established for the wild-type Dm-dNK. According to the calculations in Table 3 , the specificity for CdA increased 10-or 22-fold for B5 or B10, respectively, or 35-and 117-fold in the case of AraC. 143B cells transduced with the two mutants showed an increase in the sensitivity compared to the wild-type Dm-dNKtransduced cells. In the case of B5 and CdA the obtained sensitivities were as predicted, in all other cases they were lower than predicted (Tables 3 and 4) . It needs to be emphasized here that an increase in the sensitivity over the wild type was not expected for B10 purely based on Purine-specific Dm-dNK mutants W Knecht et al Table 2 Kinetic parameters of wild-type and mutant Dm-dNKs 
Discussion
Directed evolution or molecular breeding, employing the generation of a large number of mutants followed by selection or screening for desired features, has become a successful tool to change the properties of enzymes. For example, the catalytic rates of phosphotriesterase have been improved, 20 heme peroxidase has been modified to tolerate the 'exotic' environment inside a washing machine 21 and the thermostability of amylase, carboxypeptidase U and subtilisin increased. [22] [23] [24] We have employed this approach to generate the first generation of Dm-dNK mutants, 6 and in this study we further developed Dm-dNK mutants that work in combination with the well-known purine analogs, CdA and F-AraA. An inherent problem of directed evolution approaches is the choice of the selection or screening system, which 33 The curves show the best fit of the Hill equation to the data. Abbreviations: AraC, cytarabine; CdA, cladribine; F-AraA, fludarabine; ND, not done. The cell lines used were the osteosarcoma cell line 143B, the glioblastoma cell line U-87M-G and the breast cancer cell line MCF7. The -fold of decrease in IC 50 compared to the IC 50 of the untransduced parental cells is given in brackets. IC 50 are average from up till three independent experiments. a Data from one experiment only.
Purine-specific Dm-dNK mutants W Knecht et al often allows selection for only one parameter and this system is often very much simplified to allow for the need of high throughput. In our approach the improved ability of the Dm-dNK mutants, when expressed in E. coli to kill its host in the presence of different NAs for selection, is used as one criterium (Table 1) . However, to further characterize the mutants and gain information that would help us to select the best mutant for testing in cancer cell lines, we conducted an extensive kinetic characterization of the mutant enzymes (Tables 2 and 3 ). The aim was to develop a qualitative and quantitative approach to predict the mutants, which could have the most optimal properties as suicide genes in the mammalian cell.
We observed a general tendency that the mutants, which had a good sensitizing effect on the transformed E. coli, had a greatly reduced k cat /K m values for the native pyrimidine substrates. On the other hand, k cat /K m values for analogs were not improved but either slightly reduced or unchanged. For the quantitative judgment, we had to conclude that the results from the kinetic studies of the recombinant enzymes did not explain the results seen in the LD 100 determinations performed with E. coli. This implies that in the E. coli host more factors than the relative competition between the NAs and the natural substrates for the active center were responsible for the outcome. Factors that could play a role here would be differences in the feedback inhibition and the relative half-life of the mutant Dm-dNKs in E. coli, as well as the NA uptake, its catabolism and the further phosphorylation to the di-and triphosphate level. Differences in the feedback regulation between wild-type Dm-dNK and mutant Dm-dNK have been described previously, 6, 25, 26 resulting mainly in a loss of inhibition by thymidine triphosphate (dTTP). In fact it has been shown that some mutant Dm-dNK instead can use dTTP as phosphate donor. Therefore, two mutants, that either had a decrease in most of the LD 100 values (B5, Table 1 ) or showed the most improved specificities in the kinetic experiments (B10, Table 3) were chosen for further tests in the cancer cell lines. However, it soon became clear that in general neither the LD 100 nor the kinetic experiments did quantitatively predict the performance of the mutants in a specific cancer line cell. An important observation was that the cell line was of crucial importance (Table 4 ). The logical consequence of our results is that the final selection of dNK mutants should preferably be made in the cancer cell line of interest. However, to the best of our knowledge, examples of directed evolution of enzymes using mammalian cell expression and selection systems involving mammalian cells from the beginning as exemplified by Knecht et al. 24 are sparse. This can be explained by the high costs, the slow growth rates of the cells and thereby lengthy screening cycle times and other technical challenges when working with mammalian cell lines instead of using E. coli as a surrogate. Therefore, a combination of the selection based on E. coli expression combined with subsequent kinetic characterization is advocated as an attractive alternative to select the most potent mutants.
In all mutant Dm-dNK NA combinations tested in cancer cell lines, the mutants enhanced the toxicity of the NA when compared to the parental cell line or when tested to the cell line transduced with wild-type Dm-dNK (Table 4) . We were also able to determine two optimal mutant Dm-dNK NA combinations for 143B osteosarcoma cells (B5 and CdA) and glioblastoma U-87M-G cells (B10 and F-AraA) that enhanced the toxicity of the purine NAs by 470-and 435-fold, respectively. Recently, Solaroli et al. 18 reported an up to 80-fold enhanced toxicity of purine NAs in 143B when transduced with previously described Dm-dNK mutants 5 constructed from the knowledge on the crystal structure of Dm-dNK. 27 Our superior enhancement of purine nucleoside toxicity in 143B cells however advocates for the use of random combination and selection rather than using only the structure-based approaches, even if nonideal surrogate screening systems have to be used.
Can we explain the structural basis for the changed properties of the mutants reported here? The mutant B10 has two mutations N45D and N64D. Recently, the N64D mutation has been determined to be crucial for the enhanced toxicity of AZT mediated by the N45D/N64D Dm-dNK double mutant, and the structure of the N64D mutant of Dm-dNK has been solved and its implication discussed in detail. 26 This mutant has been first recognized for its ability to enhance the cytotoxicity for pyrimidine analogs especially AZT by providing space for its bulky 3 0 -azide group. This was also displayed in our study by B10 when tested in E. coli (Table 1) . Surprisingly, the kinetic characterization of rB10 showed a startling improvement in the relative specificities for purine NAs and all other analogs (Table 3) , topping all other mutants, except for AZT.
From a structural point of view we cannot explain the effects of the L239P mutation that is lacking in all structures so far, because all structure determinations of Dm-dNK have been only successfully carried out with C-terminal 20 amino acid-truncated proteins, implying a very flexible C terminus in the full-length enzyme. Also the influence of the N210D cannot be explained, yet. However, both mutations, N210D and L239P, were found in three of the four mutants and were derived from a parental clone (MuB) that mediated general enhanced cytotoxicity for araC, AZT, ddA and ddC. 6 It is therefore tempting to speculate that one of these, or the combination of these mutations, has a general effect on Dm-dNK helping to enhance the toxicity of NAs while the shift of specificity is defined by the other mutations. This is also in line with the fact that the V84A mutation found in B2 and B5 is an exchange from the amino acid found in Dm-dNK to the alanine found at the same position in human dCK. The V84A mutant of Dm-dNK has been shown before to accept dCyd as its preferred substrate. 5 The T85A mutation in B15 is located just beside and for all three expressed recombinant mutants, rB2, rB5 and rB15, dCyd became the most preferred substrate (Table 2) regardless the differences with the other mutation sites.
In conclusion, our study revealed two mutant DmdNKs that enhance the cellular toxicity of the purine NAs and anticancer drugs cladribine and F-AraA when expressed in glioblastoma U-87-MG and osteosarcoma 143B cells. These unique properties should be further investigated to clarify the suitability in enzyme-mediated suicide gene therapy of cancer. Our study also reveals that a future development of dNK mutants for suicide gene therapy should ideally be pursued in a mammalian cell background close to the tumor to be targeted. However, a combination of selection and subsequent Purine-specific Dm-dNK mutants W Knecht et al supplemented with 0.2% glucose, 40 mg/ml isoleucin, 40 mg/ml valin, 100 mg/ml ampicillin and with or without NAs. The kinase gene was expressed at the noninduced residual level activity. Concentrations of 0.05 mM AZT, 1 mM ddA, 100 mM ddC, 5 mM AraC, 5 mM CdA and 1 mM AraA were used for screening. Growth of colonies was visually inspected after 24 h incubation at 371C. From clones not growing on NA-containing plates, but growing normally on plates without the NA, the plasmid was isolated and retransformed into KY895. These clones were retested to verify the plasmid-born phenotype. The sequence was determined by DNA sequencing.
Determination of LD 100
All clones with increased sensitivity toward at least one NA were tested on M9 plates with logarithmic dilutions of the NAs to determine the LD 100 of the NAs, at which no growth of bacteria could be seen.
Recombinant expression and purification of the mutant enzymes
The E. coli strain KY895 was transformed with the various expression plasmids using standard techniques. Transformed KY895 were grown to an OD 600 nm of 0.5-0.6 in LB/ampicillin (100 mg/ml) medium at 371C and protein expression was induced by addition of 100 mM isopropyl-b-D-thiogalactopyranoside. The cells were further grown for 4 h at 251C and subsequently harvested by centrifugation. Pellets were stored at À801C until protein purification.
The cell pellet was homogenized by sonication in the binding buffer A (20 mM NaPO 4 , pH 7.3; 150 mM NaCl; 10% glycerol and 0.1% Triton X-100) in the presence of a protease inhibitor cocktail (Complete, ethylenediaminetetraacetic acid free from Roche Dignostics), subjected to centrifugation at 10 000 g for 30 min, filtered and loaded onto a 1 ml column (glutathione-Sepharose from Amersham Pharmacia) pre-equilibrated in binding buffer A. After loading of the sample, the column was washed with 20 ml of binding buffer A. Subsequently, the column was washed with 2.5 ml of 10 mM ATP/MgCl 2 in buffer A and incubated for 1 h at room temperature and then for 30 min at 41C. The GST-tagged protein was cleaved from the mutants on the GST-binding column by thrombin cleavage. Therefore, the column was washed again with 5 ml (A) and 1 ml of thrombin (50 U/ml) solution was applied on the column. The column was gently shaken O/N at 41C. The mutant proteins were eluted from the column in buffer A. The recombinant mutant enzymes are referred to as rB2, rB5, rB10 and rB15, respectively. Recombinant wild-type Dm-dNK (rDm-dNK) was purified as described previously.
14 The protein concentration was determined according to Bradford with BSA as standard protein. 30 SDS-PAGE was performed according to the procedure of Laemmeli 31 and proteins were visualized by Coomassie staining.
Enzyme assay
Deoxyribonucleoside kinase activities were determined by initial velocity measurements based on four time samples by the DE-81 filter paper assay using tritiumlabeled nucleoside substrates as described previously. 14 One unit (U) of dNK activity is defined as 1 mmol of the corresponding monophosphate product formed per minute.
Analysis of kinetic data
Kinetic data were evaluated by nonlinear regression analysis using the Michaelis-Menten equation
) as described in Knecht et al. 32 The equations were fitted to all available data in a global fit. K m is the Michaelis constant, K 0.5 defines the value of the substrate concentration [S] at which v ¼ 0.5V max and h is the Hill coefficient. 33, 34 If h ¼ 1, there is no cooperativity.
Construction of a retrovirus vector expressing Dm-dNK
The cDNAs were amplified with Pfu polymerase (Stratagene, La Jolla, CA, USA) using primers with designed flanking restriction enzyme sites. PCR constructs were cloned into a retrovirus vector based on the Moloney murine leukemia virus (pLCXSN) to generate a replication-deficient recombinant retrovirus containing the different dNK kinases under the control of the 
Cell lines and retroviral transduction
Three different human cancer cell lines were purchased at American Type Culture Collection (ATCC): breast; adenocarcinoma MCF-7 (ATCC HTB-22), brain; glioblastoma U-87-MG (ATCC HTB-14) and TK-deficient bone; osteosarcoma 143B (ATCC CLR-8303). Cells were cultured in RPMI, Eagle's minimal essential medium or DMEM, respectively, with 10% (v/v) Australianoriginated fetal calf serum and 5 mg/ml of gentamicin. Cells were grown at 371C in a humidified incubator with a gas phase of 5% CO 2 . The cells were transduced with the recombinant retrovirus with 5 multiplicity of infection in fully conditioned medium mixed with 5 mg/ml of polybrene, incubated for 48 h and then cultured continuously for 3 weeks in the presence of 300-400 mg/ml Genetecin (Life Technologies Inc.).
Cell proliferation assay: cytotoxicity MCF-7, U-87-MG and 143B cells were plated at density ranges of 1500-3500 cells/well, dependent on cell line growth, in 96-well plates coated with poly-L-lysine (Sigma). The different analogs of interest were suspended in conditioned media and added after 24 h of incubation, 200 ml/well. Each experiment was performed in four replicates in up to three independent experiments. Cell survival was assayed after 96-120 h of drug exposure by XTT cell proliferation kit (Roche). The data were corrected for background media-only absorbance after which the 50% cell killing drug concentration (IC 50 value) was calculated using SigmaPlot (SPSS Science, Dyrberg Trading, Denmark).
Abbreviations
AraA, vidarabine, 9-b-D-arabinofuranosyladenine; AraC, cytarabine, 1-b-D-arabinofuranosylcytosine; AZT, azidothymidine; CdA, cladribine, 2-chloro 2 0 -deoxyadenosine; dAdo, deoxyadenosine; dCyd, deoxycytidine; ddA, dideoxyadenosine; ddC, (zalcitabine) 2 0 ,3 0 -dideoxycytidine; dGuo, deoxyguanosine; dN, deoxyribonucleoside; dNK, deoxyribnonucleoside kinase; dNMP, deoxyribonucleoside monophosphate; Dm-dNK, Drosophila melanogaster multisubstrate deoxyribonucleoside kinase; dTTP, thymidine triphosphate; dUrd, deoxyuridine; F-AraA, (fludarabine) 9-b-D-arabinofuranosyl-2-fluoroadenine; Thd, thymidine
